Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALMS

Alumis Inc.

Oct 04 • 04:00PM ET

9.74

Dollar change -0.29
Percentage change -2.89	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI IWO SCHA IWN VXF IWC SCHB VTWO RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	50.18%	Shs Outstand	44.66M	Perf Week	-12.72%
Market Cap	459.92M	Forward P/E	-	EPS next Y	-	Insider Trans	46.31%	Shs Float	23.53M	Perf Month	-17.32%
Income	-	PEG	-	EPS next Q	-1.31	Inst Own	34.19%	Short Float	6.27%	Perf Quarter	-23.61%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	8.14	Perf Half Y	-
Book/sh	-8.06	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.48M	Perf Year	-
Cash/sh	4.44	P/C	2.19	EPS next 5Y	-	ROE	-	52W Range	10.01 - 13.53	Perf YTD	-26.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-28.01%	Beta	-
Dividend TTM	-	Quick Ratio	6.73	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-2.70%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	6.73	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	31.45	Volatility	6.31% 7.46%
Employees	-	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.33
Option/Short	No / Yes	LT Debt/Eq	0.15	EPS Q/Q	-	Payout	-	Rel Volume	0.61	Prev Close	10.03
Sales Surprise	-	EPS Surprise	14.04%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	181.24K	Price	9.74
SMA20	-13.26%	SMA50	-18.89%	SMA200	-19.29%	Trades		Volume	110,852	Change	-2.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc.

Upgrade your FINVIZ experience